Curcumin Depression Meta-analysis: What the Evidence Says

Quick Answer

Curcumin Depression Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Central obesity also increases the likelihood of DR in diabetic patients. Treatment options for DR focus on controlling blood sugar and lipid levels, as well as managing eye symptoms. However, existing pharmacological treatments are not always effective and may have associated side effects. [Amini Sepide (2026); evidence level 2]
• Table 3 Table 3 P P P P P As shown in, BMI was significantly reduced in the intervention group compared with the baseline (= 0.012). [Amini Sepide (2026); evidence level 2]
• Depression is a leading cause of disability worldwide and is characterised by sustained low mood, anhedonia, anergia, and a range of associated cognitive and somatic symptoms . [Muacevic Alexander (2026); evidence level 4]
• This literature review summarises key randomised controlled trials (RCTs), meta-analyses, safety data, dosing patterns, and guideline positioning for saffron in depressive disorders, with emphasis on adult major depressive disorder (MDD) and related depressive symptomatology. [Muacevic Alexander (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For curcumin depression meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Amini Sepide (2026). The Effect of Curcumin Plus Piperine on Mental Health Status, Sleep Quality, and Anthropometric Indices in Patients with Non-Proliferative Diabetic Retinopathy: A Randomized Double-Blind Placebo-Controlled Trial. DOI: 10.4103/ijpvm.ijpvm27623. PMCID: PMC13038278. PMID: 41924225. License: https://creativecommons.org/licenses/by-nc-sa/4.0/. https://pmc.ncbi.nlm.nih.gov/articles/PMC13038278/
• Muacevic Alexander (2026). The Role of Saffron in the Treatment of Depression: A Literature Review. DOI: 10.7759/cureus.104594. PMCID: PMC13044667. PMID: 41939549. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13044667/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.